<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fertility preservation: Cryopreservation options</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fertility preservation: Cryopreservation options</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fertility preservation: Cryopreservation options</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kutluk Oktay, MD, PhD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murat Sonmezer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4182908211"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Some treatments for malignancy, medical disorders, or gender affirmation can permanently end reproductive function. Patients considering such therapies should be rapidly referred for counseling regarding options for fertility preservation. Established cryopreservation techniques to preserve fertility include freezing of embryos and gametes. With appropriate pretreatment planning and intervention, future biologic parenthood is possible. </p><p>This topic will provide an overview of cryopreservation techniques. For the purposes of this discussion, the terms "female" and "woman" refer to any patient who has female reproductive organs and the potential to be pregnant. Similarly, the terms "male" and "man" refer to patients with male reproductive organs. Clinicians should also consider the fertility preservation needs of transgender and gender nonbinary persons. </p><p>An overview of fertility preservation, the approach to fertility preservation in healthy women who wish to delay childbearing, and the fertility treatments themselves are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7429.html" rel="external">"Fertility preservation for deferred childbearing for nonmedical indications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H3132434675"><span class="h1">CANDIDATES</span><span class="headingEndMark"> — </span>Any patient who is considering gonadotoxic therapy or surgery and who wishes to preserve future fertility is a candidate for cryopreservation techniques. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conventional candidates</strong> – Postpubertal children and adults with cancer or medical diseases  (<a class="graphic graphic_table graphicRef60344" href="/d/graphic/60344.html" rel="external">table 1</a>) that require gonadotoxic therapy  (<a class="graphic graphic_table graphicRef58142" href="/d/graphic/58142.html" rel="external">table 2</a>) have traditionally been referred for a fertility preservation consultation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional candidates</strong> – Additional candidates include patients undergoing gonad extirpation as part of gender affirmation surgery, those undergoing gonadal surgery, those with genetic and metabolic disorders that result in premature gonadal failure for benign lesions, or prepubertal children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BRCA</em></strong><strong> gene mutation carriers</strong> – Studies of <em>BRCA</em> gene mutation carriers suggest these women experience accelerated ovarian aging [<a href="#rid1">1-4</a>]. A recent individual patient data meta-analysis covering &gt;80 percent of all published data on women affected with breast cancer showed that women with <em>BRCA</em> mutations, particularly of the <em>BRCA 1</em> type, have approximately 25 percent lower serum anti-Müllerian hormone (AMH) levels compared with mutation-negative controls [<a href="#rid5">5</a>]. Women with <em>BRCA</em> mutations have been reported to lose primordial follicles and accumulate DNA damage in their oocytes at an accelerated rate compared with controls [<a href="#rid6">6,7</a>]. Given that gonadotoxic chemotherapy damages oocytes by inducing DNA damage, <em>BRCA</em> mutation carriers may be more likely to lose their ovarian reserve after cancer treatments. A study of 108 women reported that those with <em>BRCA 1</em> and <em>BRCA 2</em> mutations had lower serum AMH levels following recovery after breast cancer chemotherapy compared with controls [<a href="#rid8">8</a>]. Both because of accelerated follicle loss and the risk of loss of fertility due to breast/ovarian cancer development and its associated gonadotoxic chemotherapy, women with <em>BRCA</em> mutations should have ovarian reserve assessment and be counselled about early childbearing and/or options for fertility preservation. </p><p></p><p class="headingAnchor" id="H1622882651"><span class="h1">PRETREATMENT</span><span class="headingEndMark"> — </span>Pretreatment involves procedures to obtain the cells, and potentially create the embryos, that will then be cryopreserved for future use. Typical procedures include ovarian stimulation and oocyte retrieval, semen or sperm collection, and in vitro fertilization (IVF).</p><p class="headingAnchor" id="H3700646210"><span class="h2">Oocyte retrieval</span></p><p class="headingAnchor" id="H2246682318"><span class="h3">Ovarian stimulation</span><span class="headingEndMark"> — </span>Patients wishing to cryopreserve oocytes or create embryos first undergo controlled ovarian stimulation and oocyte retrieval. Timing of stimulation to the menstrual cycle is no longer required [<a href="#rid9">9,10</a>]. The preferred ovarian stimulation protocol is the one most compatible with the patient's medical condition(s), timing, and treatment needs. (See  <a class="medical medical_review" href="/d/html/134342.html" rel="external">"In vitro fertilization: Procedure", section on 'Ovarian stimulation'</a>.)</p><p>Although oocytes can be retrieved during a natural cycle, the yield is low; hence, controlled ovarian stimulation is the preferred approach [<a href="#rid11">11</a>]. An approximate 12 to 16 day interval is adequate to complete a cycle of ovarian stimulation and egg retrieval in most patients [<a href="#rid12">12</a>]. Prompt referral to a reproductive endocrinologist may also allow time for two cycles, which typically increases the number of retrieved oocytes.</p><p>Patients who are not candidates for ovarian stimulation are counseled about the options of donor oocytes, donor embryos, gestational carriers, and adoption. (See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery", section on 'Other methods to preserve or restore fertility'</a>.)</p><p>We do not advise ovarian stimulation after chemotherapy has been initiated because the ovarian response to ovarian stimulation, likelihood of cycle cancellation, and the quality of oocytes retrieved diminish with every round of chemotherapy, including the first [<a href="#rid13">13-16</a>]. Chemotherapy induces DNA double-strand breaks in human oocytes [<a href="#rid17">17</a>] and activates apoptotic death pathways [<a href="#rid18">18</a>]. Because of this, we and others advise women who receive chemotherapy to wait six months before attempting to conceive [<a href="#rid19">19</a>], although embryo banking between induction and consolidation chemotherapy has been reported in women with leukemia [<a href="#rid20">20</a>]. Waiting six months should allow developing follicles with DNA damage to be cleared from the ovary as new follicles are recruited from surviving primordial follicles.</p><p class="headingAnchor" id="H3840788816"><span class="h3">Patients with estrogen-sensitive cancer</span><span class="headingEndMark"> — </span>Most breast cancer chemotherapy regimens, except tamoxifen-only protocols, are gonadotoxic to ovarian reserve and warrant discussion of fertility preservation [<a href="#rid21">21</a>]. Concerns have been raised about using traditional ovarian stimulation techniques in patients with estrogen-sensitive cancers because traditional protocols result in supraphysiologic estrogen levels (up to 10-fold greater), which could stimulate cancer growth [<a href="#rid22">22-24</a>]. Estrogen-minimizing ovarian stimulation protocols have been devised, particularly for women with breast cancer [<a href="#rid25">25</a>]. The two most common agents used for controlled ovarian stimulation in these patients are <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> and <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. Breast cancer patients who undergo ovarian stimulation with these agents do not appear to have an increased risk of disease recurrence or death, but data are limited [<a href="#rid26">26,27</a>]. At least one trial is underway to directly compare the efficacy of these treatments in women with breast cancer [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2875265375"><span class="h4">Letrozole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">Letrozole</a>, an aromatase inhibitor that is used in combination with gonadotropins, is the preferred stimulant for IVF cycles in women with breast cancer [<a href="#rid29">29</a>]. While pregnancy rates are impacted by patient age, type of cancer therapy, and partner factors, general pregnancy rates of 25 to 35 percent have been reported [<a href="#rid30">30</a>]. An advantage of ovarian stimulation with aromatase inhibitors is that peak estradiol levels are close to those observed in natural cycles [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/7425.html" rel="external">"Ovulation induction with letrozole"</a>.)</p><p>We prefer a letrozole-follicle-stimulating hormone (FSH) protocol for ovarian stimulation in breast cancer patients undergoing IVF for embryo or oocyte cryopreservation because the combination results in low estradiol exposure and high oocyte recovery. In a prospective sequential cohort study comparing <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> and <a class="drug drug_general" data-topicid="8780" href="/d/drug information/8780.html" rel="external">anastrozole</a> for ovarian stimulation in 54 patients with breast cancer, length of stimulation, total gonadotropin dose, number of follicles larger than 17 mm, and number of embryos cryopreserved were similar between the two groups [<a href="#rid33">33</a>]. However, the mean estradiol levels on the day of human chorionic gonadotropic (hCG) and post-hCG days were higher in the anastrozole group compared with the letrozole group. Anastrozole appears to result in significantly higher estradiol exposure than letrozole as it does not sufficiently suppress aromatase activity in the ovarian stimulation setting [<a href="#rid33">33</a>]. A meta-analysis demonstrated reassuring results with letrozole-gonadotropin ovarian stimulation regarding the number of retrieved MII oocytes, total number of oocytes, maturation rate, fertilization rate, and number of cryopreserved embryos [<a href="#rid34">34</a>]. Thus, we prefer letrozole-containing protocols, as above. Data on ovarian stimulation with other aromatase inhibitors are lacking.</p><p>The ovarian stimulation medications, including <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, can be started at a random time in the cycle without compromising fertilization rates, which has been referred to as "random start controlled ovarian stimulation" [<a href="#rid9">9,10</a>]. Studies have demonstrated a good safety profile with no increased risk of disease recurrence or decrease in survival, even for repeat cycles [<a href="#rid35">35,36</a>]. In a systematic review of 15 studies that evaluated mortality and recurrence after ovarian stimulation in women with early breast cancer, the relapse-free survival rates were similar among women with breast cancer who received ovarian stimulation with letrozole compared with women with breast cancer who did not undergo fertility preservation procedures [<a href="#rid27">27</a>]. The largest of the included studies reported recurrences in 6/120 women (5.0 percent) who received ovarian stimulation plus letrozole compared with 12/217 women (5.5 percent) who did not undergo ovarian stimulation (hazard ratio for recurrence 0.77, 95% CI 0.28-2.13). </p><p class="headingAnchor" id="H1965227477"><span class="h4">Tamoxifen</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, a selective estrogen receptor modulator with antiestrogenic actions on breast tissue, is as effective as <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate in the treatment of anovulatory infertility and thus appears to be useful in women with breast cancer, we prefer using aromatase inhibitors combined with FSH over tamoxifen plus FSH because the oocyte yield is similar but the estrogen exposure is lower with letrozole-FSH [<a href="#rid31">31,37</a>]. However, in instances of contraindications to <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> use (eg, drug sensitivity) or if the patient does not wish to stop long-term tamoxifen therapy, we use tamoxifen-FSH as an alternative regimen [<a href="#rid38">38</a>]. </p><p>The utility of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> for ovarian stimulation in women with breast cancer was illustrated in a prospective study that examined the effectiveness and safety of tamoxifen for ovarian stimulation in breast cancer patients and then compared these results with a retrospective control group of breast cancer patients who had natural cycle IVF [<a href="#rid39">39</a>]. Patients stimulated with tamoxifen had fewer cancelled cycles (1/15 versus 4/9) and a higher number of mature oocytes (1.6±0.3 versus 0.7±0.2 in controls) and total embryos (1.6±0.3 versus 0.6±0.2 in controls). An embryo could be generated in 12 of 12 patients stimulated with tamoxifen; by contrast, natural cycle IVF resulted in embryos in only three of five patients. Although the peak estradiol levels were higher in the tamoxifen group than in unstimulated controls, cancer recurrence rates were not increased after a mean follow-up of approximately two years [<a href="#rid31">31</a>]. Others have reported no increase in breast cancer recurrence up to 10 years after coadministration of tamoxifen and conventional controlled ovarian stimulation for IVF [<a href="#rid40">40</a>]. </p><p>Studies directly comparing <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> with <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> in this population are small. </p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective study that compared the oocyte yield among women using <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> alone (n = 12), those using FSH combined with tamoxifen (n = 7), and women using FSH combined with <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> (n = 11), there was no significant difference in number of oocytes retrieved between the letrozole-FSH and tamoxifen-FSH groups [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A different trial reported similar mature oocyte yield between the tamoxifen-gonadotropin (45 patients) and letrozole-gonadotropin (51 patients) groups (12±8.6 versus 11.6±7.5) [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized open-label trial has been registered to compare ovarian stimulation plus <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and ovarian stimulation plus <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> with standard ovarian stimulation for fertility preservation in breast cancer patients [<a href="#rid28">28</a>]. </p><p></p><p class="headingAnchor" id="H1974706961"><span class="h3">Options for women who cannot undergo ovarian stimulation</span><span class="headingEndMark"> — </span>When ovarian stimulation is not possible for time or safety issues, such as women with large or locally advanced breast cancers, harvesting of immature oocytes is an option [<a href="#rid42">42</a>]. One advantage of harvesting immature oocytes is that the procedure can be performed at any point in the menstrual cycle. Following retrieval, immature oocytes are cultured (in vitro maturation); mature oocytes are then cryopreserved. (See <a class="local">'Oocytes'</a> below.)</p><p class="headingAnchor" id="H4203793158"><span class="h2">Sperm collection</span><span class="headingEndMark"> — </span>Successful sperm collection after masturbation has been reported for boys aged 12 years and older [<a href="#rid43">43-46</a>]. In one study of over 4000 adolescents and young adults, successful sperm collection by masturbation was performed in 81 percent of 11 to 14 year olds, 91 percent in 15 to 17 year olds, and 95 percent in 18 to 20 year olds [<a href="#rid43">43</a>].</p><p>When no sperm are found in an ejaculate or if the patient is unable to ejaculate, sperm may be recovered by epididymal sperm aspiration or testicular sperm extraction (TESA) [<a href="#rid47">47,48</a>]. Patients who were previously considered sterile due to persistent postchemotherapy azoospermia may also benefit from TESA. In one study, sperm could be recovered by TESA performed by a microsurgical technique in 9 out of 20 patients who were rendered azoospermic due to prior chemotherapy [<a href="#rid47">47</a>]. Following intracytoplasmic sperm injection of the partner's oocytes, clinical pregnancy was achieved in three patients, resulting in term deliveries in two patients.</p><p>Transrectal electroejaculation may be utilized to collect sperm in patients who experience ejaculation problems secondary to previous surgical procedures or neurologic disease and possibly in pubertal boys unable to produce a sample through masturbation [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2817444617"><span class="h2">In vitro fertilization</span><span class="headingEndMark"> — </span>Patients who desire only preservation of gametes go through the collection processes above and then stop short of using those gametes to create embryos. However, embryo cryopreservation was developed before oocyte cryopreservation and is a well-established technique. Embryo creation requires both oocyte and sperm. Use of donor gametes is an option if autologous ones are not available. These reproductive techniques are presented in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7423.html" rel="external">"Donor insemination"</a>.)</p><p></p><p class="headingAnchor" id="H1119416440"><span class="h1">CRYOPRESERVATION</span><span class="headingEndMark"> — </span>Established cryopreservation techniques include freezing of embryos, oocytes, ovarian tissue, and spermatozoa  (<a class="graphic graphic_table graphicRef65144" href="/d/graphic/65144.html" rel="external">table 3</a>) [<a href="#rid50">50,51</a>]. Ovarian tissue cryopreservation is no longer considered investigational [<a href="#rid52">52</a>]. Cryopreservation of testicular tissue is available in some centers [<a href="#rid53">53</a>] and offered as part of a research protocol [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H3106367050"><span class="h2">Freeze-thaw survival</span><span class="headingEndMark"> — </span>There is no evidence to support that cryopreserved embryos, oocytes, or ovarian tissue deteriorates with long-term storage, and clinical experience demonstrates that they can be viably stored for decades. When slow freezing is used, frozen embryos survive the freeze-thaw process better than unfertilized oocytes (&gt;90 percent survival versus 70 to 90 percent survival) [<a href="#rid54">54,55</a>].With the use of vitrification, survival rates of oocytes approach those of embryos [<a href="#rid56">56</a>]. Purely from the perspective of cumulative success rates, embryo cryopreservation may be preferable to oocyte cryopreservation when possible. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of fresh eggs</strong> – In some studies, blastocyst embryo formation rates were reported to be 50 percent higher with fresh eggs than frozen eggs [<a href="#rid57">57</a>]. Even with egg donation, clinical success rates are lower with frozen versus fresh eggs [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy versus live birth rates</strong> – A society guideline concluded that although there are no significant differences in per-transfer pregnancy rates with cryopreserved versus fresh donor oocytes, there is insufficient evidence that the live birth rate is the same with vitrified versus fresh donor oocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal outcomes</strong> – Neonatal outcomes appear similar with cryopreserved oocytes compared with fresh oocytes [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/133130.html" rel="external">"Assisted reproductive technology: Infant and child outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of oocyte cryopreservation</strong> – Oocyte cryopreservation provides more flexibility for the female partner. As an example, a woman who donated her oocyte to create an embryo as part of a couple may no longer be able to use the resultant embryo if the relationship dissolves. Many centers are offering a combination of fertilizing some oocytes, creating embryos for cryopreservation, and simultaneously cryopreserving some mature oocytes to permit future flexibility.</p><p></p><p>However, it is important to discuss with patients that cryopreservation of embryos or oocytes does not guarantee preservation of fertility. Even if there is good survival, not all patients conceive and age-related increases in chromosomal abnormalities result from meiotic dysfunction in oocytes. To reduce the risk of chromosomal abnormality, the authors perform preimplantation genetic testing on embryos generated for fertility preservation purposes [<a href="#rid60">60</a>]. However, the feasibility of this approach in the setting of fertility preservation has not been evaluated in large scale studies.</p><p class="headingAnchor" id="H510421970"><span class="h2">Embryo</span><span class="headingEndMark"> — </span>Cryopreservation of embryos is the most established technique for preserving reproductive capacity [<a href="#rid61">61</a>]; cryopreserved, thawed embryos are used in approximately 20 percent of all assisted reproductive technology cycles [<a href="#rid62">62</a>]. Live birth rates following frozen embryo transfer in infertile patients under the age of 35 approach 45 percent [<a href="#rid63">63</a>]. Success rates may be higher in fertility preservation patients who do not have preexisting conditions affecting fertility [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'Live birth and IVF'</a>.)</p><p>Cryopreservation of embryos may not be technically feasible for every patient planning gonadotoxic therapy for several reasons:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time constraints </strong>– Since gonadotoxic treatment is usually implemented quickly after cancer diagnosis, there may not be adequate time for ovarian stimulation and oocyte retrieval, which usually requires a minimum of two weeks. Options to minimize the amount of time required include retrieval of immature oocytes followed by in vitro maturation or use of random-start ovarian stimulation protocols [<a href="#rid9">9,65-68</a>]. (See <a class="local">'Options for women who cannot undergo ovarian stimulation'</a> above and <a class="local">'Letrozole'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No partner</strong> –<strong> </strong>Embryo preservation can be used by women with an available male partner or who elect to use donor sperm to create embryos rather than egg freezing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Legal and ethical issues </strong>–<strong> </strong>Ovarian stimulation for embryo freezing may not be ethically acceptable in postmenarchal children with cancer. Some couples may be philosophically opposed to cryopreservation of embryos, and this is only performed under strictly controlled embryo protection laws. It is illegal in some countries (eg, Germany, Switzerland, Italy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen-sensitive tumors </strong>– Estrogen-sensitive tumors might be stimulated by the high estrogen levels resulting from ovarian stimulation. (See <a class="local">'Patients with estrogen-sensitive cancer'</a> above.)</p><p></p><p class="headingAnchor" id="H3922576343"><span class="h2">Oocytes</span></p><p class="headingAnchor" id="H2228873091"><span class="h3">Mature oocytes</span><span class="headingEndMark"> — </span>Cryopreservation of mature oocytes is an option for women without partners, women who may have partners but are concerned about the practical limitations with embryo cryopreservation, or women who opt not to use donor sperm for in vitro fertilization (IVF). In contrast to cryopreservation of embryos and sperm, oocyte cryopreservation is technically more challenging since oocytes contain more water and thus are more sensitive to cryoinjury from formation of ice crystals [<a href="#rid69">69</a>]. The meiotic spindle, cytoskeleton, cortical granules, and zona pellucidae are the structures particularly at risk from freezing. However, by using special freezing techniques, approximately 70 percent of cryopreserved oocytes survive the freeze-thaw process [<a href="#rid70">70,71</a>] and possibly as many as 90 percent with newest protocols [<a href="#rid72">72,73</a>].</p><p>In randomized trials, the pregnancy rate with cryopreserved/warmed mature oocytes was generally similar to that with fresh oocytes, although these trials were largely limited to donor oocyte populations and infertile couples with supernumerary oocytes [<a href="#rid57">57,74-77</a>]. Two large observational studies reported acceptable success rates but lower than with fresh oocytes [<a href="#rid78">78,79</a>]. Oocyte cryopreservation is no longer considered investigational. </p><p>The two methods of cryopreservation are the "slow-freeze" technique and vitrification (conversion of water to a solid without formation of ice crystals by using a very "fast freeze" and cryoprotectants). Vitrification is now the preferred method as it results in higher survival, implantation, and pregnancy rates compared with slow freezing [<a href="#rid56">56,80,81</a>]. The authors have created an <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fertilitypreservation.org%2Fcontents%2Fprobability-calculator&amp;token=DNOTQ9ERbYVPxeJ8tmtl6m4%2BaIBUCBDKEn%2FiY09%2FFKosEhkLQEluEUJ2sA2WRCkDMze7W%2BCnQIeLAS1i%2Br2CPy0je96fDx2ET5HH0r20nvw%3D&amp;TOPIC_ID=121395" target="_blank">online</a> tool that may be useful for counseling women regarding likelihood of successful egg freezing [<a href="#rid82">82</a>]. </p><p>There is a theoretical concern that damage to the metaphase spindle of the oocyte during oocyte cryopreservation could increase the risk of karyotypic abnormalities in offspring. Such defects have not been demonstrated in clinical studies, but experience is limited. The authors have demonstrated the feasibility of transvaginal oocyte retrieval and cryopreservation in young adolescent girls with cancer and mosaic Turner syndrome [<a href="#rid83">83-85</a>]. In young adolescent cancer patients or patients with sociocultural concerns regarding virginity, abdominal retrieval of oocytes following ovarian stimulation has also been offered [<a href="#rid86">86</a>]. The American Society for Reproductive Medicine has published guidelines for informed consent prior to elective oocyte cryopreservation [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H2528817105"><span class="h3">Immature oocytes</span><span class="headingEndMark"> — </span>Immature oocytes have been harvested from both in situ and excised ovarian tissue [<a href="#rid88">88-90</a>]. Development of the technique and assessment of its role in fertility treatment are ongoing [<a href="#rid91">91</a>]. The immature oocytes are matured in vitro (ie, in vitro maturation [IVM]) either before freezing or after thawing [<a href="#rid92">92</a>]; however, fresh oocytes have higher IVM rates than frozen oocytes [<a href="#rid93">93-95</a>]. A study questioned the utility of performing IVM in very young premenarchal girls because IVM rates were particularly low for girls younger than four years of age [<a href="#rid96">96</a>]. However, further studies are required to confirm this conclusion, as the authors' unpublished experience differs with that report.</p><p>Compared with conventional ovarian stimulation and retrieval of mature oocytes, advantages include the avoidance of large doses of gonadotropins and their associated risks and high costs, as well as avoidance of time constraints and exposure of estrogen-sensitive tumors to high estrogen levels [<a href="#rid97">97</a>]. In addition, immature oocytes are expected to be more resistant to cryoinjury than mature oocytes since they do not contain a metaphase spindle. </p><p>However, the implantation rate per embryo transferred (5.5 to 21.6 percent) is significantly lower, and early pregnancy loss per embryo transferred is higher than in conventional IVF [<a href="#rid98">98</a>]. The success rates of IVM in women with polycystic ovarian morphology with the use of follicle-stimulating hormone (FSH) priming is much higher compared with women having a regular menstrual cycle (implantation rates 47.7 and 11.8 percent, respectively) [<a href="#rid99">99</a>]. Reliable data on the success of IVM in a fertility preservation population are lacking. However, in women with breast cancer undergoing ovarian stimulation with the letrozole-FSH protocol, the authors reported higher than expected IVM rates [<a href="#rid100">100</a>]. Few pregnancies from frozen-thawed immature human oocytes have been reported, and, although follow-up studies of these children are limited, their results have been reassuring [<a href="#rid101">101-103</a>].</p><p class="headingAnchor" id="H2320219085"><span class="h2">Ovary</span><span class="headingEndMark"> — </span>This technique has the advantage of restoring ovarian endocrine function as well as the ability to conceive [<a href="#rid29">29</a>]. Cryopreservation of ovarian tissue is not an option for women with ovarian cancer or those at high risk of developing ovarian cancer.</p><p class="headingAnchor" id="H4206652576"><span class="h3">Whole ovary and pedicle</span><span class="headingEndMark"> — </span>Cryopreserving the entire ovary with its vascular supply might help decrease the degree of follicle loss during the initial ischemia period after transplantation, but it has been difficult to preserve both the ovarian follicles and ovarian vascular pedicle [<a href="#rid104">104-108</a>]. Techniques that efficiently cryopreserve both the ovary and its vascular pedicle have not yet been developed.</p><p class="headingAnchor" id="H3328300951"><span class="h3">Ovarian tissue</span><span class="headingEndMark"> — </span>With ever-increasing success rates following the transplantation of cryopreserved ovarian tissue and with its unique advantage of restoration of ovarian endocrine function, this technique is considered an established method of fertility preservation [<a href="#rid29">29,52</a>].</p><p class="headingAnchor" id="H893162718"><span class="h4">Procedure</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques</strong> – While ovarian tissue cryopreservation followed by autotransplantation has been considered as an investigational method in general, orthotopic ovarian transplantation (eg, to remaining ovarian tissue or pelvic peritoneum) is now considered a standard clinical technique in several countries [<a href="#rid52">52,59</a>]. After initial controversy surrounding the success of the technique, the first ongoing pregnancy following heterotopic grafting of cryopreserved ovarian tissue was reported in 2013 [<a href="#rid109">109-116</a>]. </p><p></p><p class="bulletIndent1">Cryopreservation of ovarian tissue followed by heterotopic implantation (eg, in the abdominal wall, forearm, chest wall) remains an investigational approach, mainly because long-term outcome data are not as well established as for embryo cryopreservation [<a href="#rid117">117,118</a>]. In the authors' experience, heterotopic ovarian transplantation is more suitable when the primary goal is to restore hormone production and/or pelvic transplantation is not feasible for medical reasons. Even though the slow freezing method has been used as the standard technique to freeze ovarian fragments, some studies suggested the effectiveness and safety of vitrification [<a href="#rid119">119,120</a>]. However, clinical outcome data are limited with ovarian transplants using vitrified tissue, and further data will be needed before vitrification can replace slow ovarian tissue freezing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates</strong> – Potential candidates for ovarian tissue cryopreservation include patients who require immediate gonadotoxic treatment, those undergoing repeated ovarian surgeries for benign ovarian lesions, and prepubertal girls. When compared with embryo cryopreservation, advantages include that neither ovarian stimulation nor a partner are needed and that implanted ovarian tissue can continue to produce hormones. </p><p></p><p class="bulletIndent1">When possible, ovarian tissue should be obtained before chemotherapy since ovarian reserve is diminished with each round of chemotherapy [<a href="#rid121">121,122</a>]. However in our clinical experience, when ovarian tissue is cryopreserved from patients &lt;25 years of age, live births have been achieved even in women who were exposed to chemotherapy before tissue cryopreservation [<a href="#rid123">123</a>]. Each case should be individualized based on the patient's age, amount and type of prior chemotherapy exposure, and other available options.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined techniques</strong> – In attempt to ensure future fertility, immature oocytes can be retrieved from the harvested ovarian tissue and frozen separately as an adjunct to ovarian tissue cryopreservation [<a href="#rid88">88</a>]. All egg-containing follicles are in the outer 1 millimeter of the ovary, so cryopreservation can be limited to only this strip of tissue. The combination of partial removal of ovarian tissue for ovarian cryopreservation followed by ovarian stimulation and cryopreservation of oocytes can improve the efficacy of fertility preservation without compromising the average number and quality of retrieved oocytes [<a href="#rid124">124</a>]. A subsequent study demonstrated that a higher mean number of oocytes was collected ex vivo from removed ovarian tissue in girls compared with adults, but the percentage of degenerated oocytes was significantly higher in girls [<a href="#rid125">125</a>]. </p><p></p><p class="headingAnchor" id="H2133897659"><span class="h4">Patient selection</span><span class="headingEndMark"> — </span>Consensus is lacking on patient selection criteria; protocols can be more or less restrictive. One challenge is the relatively small number of patients in the available studies to inform practice. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Edinburgh criteria</strong> – Edinburgh criteria are strict selection criteria that have been proposed for selecting candidates for ovarian cryopreservation [<a href="#rid126">126,127</a>]. These criteria limit the procedure to girls/women under age 35 with no children and with at least a 50 percent risk of ovarian failure after cancer therapy [<a href="#rid128">128</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – We do not adhere to such strict criteria as we believe there are many more variables that need to be considered in patient selection, including that ovarian reserve testing does not predict fertility, patients with children may desire additional children, and the fact that technology continues to advance [<a href="#rid17">17,129,130</a>]. Studies that inform our approach include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A case series that involved transplantation of ovarian cortical pieces sutured onto an extracellular matrix scaffold reported successful transplantation in six of seven patients and a total of seven live births across four patients [<a href="#rid131">131</a>]. Although six of the patients had been exposed to gonadotoxic chemotherapy prior to tissue cryopreservation, which would have made them ineligible based on strict selection criteria, endocrine function was restored in all cases with a significantly longer graft longevity compared with patients in a meta-analytic database, where incidence of prior exposure to chemotherapy was significantly lower. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In our opinion, prior exposure to chemotherapy should not be considered a contraindication for ovarian tissue cryopreservation. This is especially true in younger patients where primordial follicle oocytes' ability to repair chemotherapy-induced DNA double strand breaks is higher than for older patients [<a href="#rid4">4,18,132-134</a>].</p><p></p><p class="headingAnchor" id="H884379180"><span class="h4">Outcomes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft longevity</strong> – In a study assessing the impact of robot-assisted autologous cryopreserved ovarian tissue transplantation with the use of a neovascularizing extracellular matrix scaffold, the mean graft longevity (43.2 ± 23.6 with sensitivity analysis) trended longer than the meta-analytic mean (29.4 ± 22.7), even after matching age at cryopreservation. This difference was achieved despite the fact that a higher proportion of recipients had received gonadotoxic chemotherapy before tissue cryopreservation compared with the meta-analytic control [<a href="#rid118">118,131</a>]. These findings suggest that new transplantation approaches may improve graft longevity [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cumulative pregnancy and live birth rates</strong> – Ovarian tissue transplant has resulted in cumulative ongoing pregnancy and live birth rates of 25 to 37 percent [<a href="#rid118">118,131</a>]. Pregnancy rates vary by age of the patient at time of gamete cryopreservation, surgical experience and technique, and the patient's comorbid medical conditions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2017 meta-analysis of 19 studies on OTT that included pregnancy-related outcomes, 309 OTTs resulted in 84 live born children and 8 ongoing pregnancies, for cumulative clinical pregnancy and composite pregnancy rates (live birth plus ongoing pregnancy) of 57.5 and 37.7 percent, respectively [<a href="#rid118">118</a>]. Sixty-four percent of patients experienced restored endocrine function. Approximately two-thirds (62.3 percent) of the patients conceived naturally. For comparison, IVF frozen-thawed embryo transfers results in live birth rates of 22 to 35 percent, depending on the age of the mother [<a href="#rid136">136</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An update of a meta-analysis identified 518 patients who received 631 autologous transplants with cryopreserved ovarian tissue that resulted in 141 livebirths (147 infants) and 11 ongoing pregnancies [<a href="#rid118">118,131</a>]. After excluding studies with inadequate data and patients who did not desire pregnancy, the calculated pregnancy rate was 25 percent per transplant (115 live births or ongoing pregnancies in 460 recipients) [<a href="#rid131">131</a>]. In a subgroup of seven patients who underwent robot-assisted ovarian tissue transplantation involving a neovascularizing extracellular matrix, all were able to attain gametes and a total of seven babies have been born to four of the patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative impact of increasing patient age</strong> – Similar to conventional conception or IVF, increasing patient age at the time of ovarian tissue cryopreservation is associated with reduced live birth rates. In a registry study including 244 transplantations in 196 patients, the live birth rate dropped from 29.2 percent (95% CI 20.9-36.3) for patients &lt;35 years to 16.7 percent (95% CI 7.9-29.3) for patients ≥35 years [<a href="#rid137">137</a>]. The majority of pregnancies after ovarian tissue graft have occurred in patients who were younger than 30 years old at the time of the cryopreservation procedure, including a postpubertal but premenarchal girl and a prepubertal girl [<a href="#rid138">138-141</a>]. Moreover, the pregnancy rate was higher after the first transplantation (30.6 percent [95% CI, 24.2-37.6]) compared with the second and subsequent transplantations (11.8 percent [95% CI, 3.3-27.5]). (See  <a class="medical medical_review" href="/d/html/111561.html" rel="external">"Evaluation and management of infertility in females of advancing age", section on 'Biology of female fertility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of menstrual patterns</strong> – In a review of data from five European centers, the live birth rate was reported as 30.6 percent (15 of 49) in women who had persistent irregular menses while undergoing OTT and 25.4 percent (54 of 212) in women who had amenorrhea before OTT [<a href="#rid142">142</a>]. </p><p></p><p class="headingAnchor" id="H4263468018"><span class="h4">Ovarian tissue transplant for patients with cancer</span><span class="headingEndMark"> — </span>Ovarian tissue preservation may <strong>not</strong> be an ideal option for patients with ovarian cancer, those at high risk of developing ovarian or breast cancer, or those with blood malignancies (ie, leukemias) [<a href="#rid29">29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary ovarian cancer syndromes</strong> – Patients with mutations in breast cancer susceptibility genes (<em>BRCA1</em> or <em>BRCA2</em>) have significantly elevated lifetime risks of cancer  (<a class="graphic graphic_table graphicRef68548" href="/d/graphic/68548.html" rel="external">table 4</a>). These women are offered prophylactic oophorectomy (usually at the completion of childbearing) to decrease the risk of developing ovarian cancer or as a part of a treatment plan for breast cancer [<a href="#rid143">143</a>]. They are not ideal candidates for cryopreservation of ovarian tissue, given their increased risk of developing ovarian cancer and the relatively high incidence of occult ovarian cancer (2.0 to 18.5 percent) in<em> BRCA</em> carriers. (See  <a class="medical medical_review" href="/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer transmission and potential risk reduction</strong> – We believe that patients with hereditary breast-ovarian cancer syndromes can safely undergo ovarian tissue preservation and transplantation by using strategies to limit risk of subsequent cancer transmission or development. Mitigation strategies include harvesting ovarian tissue at an early age when risk of ovarian cancer is negligible and then pausing potential cancer development with cryopreservation. At transplantation, the patient's ovarian cancer risk would then resume from a lower-risk biologic tissue age. However, these assumptions have not yet been tested in studies and not all experts agree. If ovarian tissue is cryopreserved for reimplantation, a detailed histologic analysis of the ovarian cortical pieces is mandatory but may not completely exclude the presence of ovarian cancer. (See  <a class="medical medical_review" href="/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reduced ovarian reserve</strong> – Another disadvantage for women with BRCA mutations is that they appear to have accelerated ovarian aging and lower ovarian reserve compared with those without the mutations. A individual data meta-analysis from five centers worldwide showed that serum AMH levels were approximately 25 percent lower in women with BRCA mutations who were affected with cancer, compared with those who did not carry these mutations [<a href="#rid5">5</a>]. The results were similar after adjustment for age, birth control pill use, the center, body mass index (BMI), and other factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> – Early stage infiltrative ductal breast cancer, the most common histologic subtype, rarely metastasizes to the ovaries, in contrast to lobular breast cancer, which usually occurs during later years of life [<a href="#rid144">144</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cancers</strong> – In women with cancer not involving the ovary, there is a theoretical concern of reimplantation of metastatic cells from the primary tumor during autotransplantation. However, the majority of the tumors encountered during reproductive ages have relatively low potential to metastasize to ovaries [<a href="#rid145">145,146</a>]. In the authors' series of 55 women with various malignancies undergoing ovarian tissue cryopreservation, no ovarian metastases were found on histologic analysis of tissue samples [<a href="#rid147">147</a>]. Exceptions include blood-borne malignancies, such as leukemias [<a href="#rid148">148-151</a>], as well as Burkitt lymphoma and neuroblastoma. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukemia </strong>– Leukemia may not be a strict contraindication for ovarian tissue cryopreservation, as most of the candidates are in remission waiting for hematopoietic stem cell transplantation. In our and others' limited experience, no recurrence of leukemia has been observed after ovarian autotransplantation [<a href="#rid152">152,153</a>]. In a study of six patients with leukemia who had been treated with hemapoietic stem cell transplant, no cancer was detected during a median of 41 months of follow-up and ovarian function returned in all patients [<a href="#rid154">154</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphoma</strong> – Animal studies indicate that the likelihood of ovarian involvement is not high in Hodgkin lymphoma, but the possibility of transmission cannot be excluded completely [<a href="#rid155">155,156</a>]. The only series in humans with lymphoma reported that none of the 26 patients had evidence of ovarian involvement by histology and immunohistochemistry [<a href="#rid157">157</a>]. </p><p></p><p>Although cryopreservation procedures generally should not be performed for the purpose of future autotransplantation when there is a significant concern about cancer involving the ovaries, there are possible exceptions. Ovarian tissue cryopreservation can be offered in patients with no recourse even when the risk of cancer cell presence in the ovary is high, as long as the patient understands that the ovary will not be replaced until and unless a safer method of utilization of such tissue, such as the in vitro growth of primordial follicles, is developed. A thorough histologic evaluation should be done on portions of harvested ovarian tissue to rule out micrometastases prior to cryopreservation. If available, molecular markers can also be utilized to detect an extremely small number of metastatic cells in the tissue [<a href="#rid149">149,158</a>]. </p><p class="headingAnchor" id="H790164098"><span class="h3">Transplantation after cryopreservation</span><span class="headingEndMark"> — </span>For women who have undergone ovarian tissue, or theoretically whole ovary, cryopreservation for fertility preservation, the stored tissue is thawed and reimplanted (transplanted) at a future date following treatment. That tissue can be placed in the native location of the same patient (autologous orthotopic), a different anatomic location in the same patient (autologous heterotopic), or in a different individual (nonautologous). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous orthotopic OTT</strong> –<strong> </strong>Until it is technically possible to cryopreserve a whole ovary, ovarian cortex is cryopreserved in small strips. In the orthotopic technique, these thawed strips are transplanted to the remaining ovary, pelvic side wall, or mesosalpinx using laparoscopic or robot-assisted techniques [<a href="#rid123">123</a>]. The authors reconstruct the ovarian graft on a human extracellular matrix scaffold with a microsurgical approach before transplanting with a robot-assisted technique [<a href="#rid123">123,159-161</a>].</p><p></p><p class="bulletIndent1">Although transplanted ovarian tissue has remained functional for close to ten years in rare patients, most patients experience a limited functional lifespan of the graft [<a href="#rid162">162</a>]. Thus, cryopreserved ovarian tissue is not autotransplanted until the woman is ready to conceive and has received medical clearance from her oncologist. It may take two to five months before the transplanted ovarian tissue begins to function. If additional cryopreserved ovarian tissue is available, a second heterotopic autotransplant can be performed if the initial ovarian transplant function wanes [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous heterotopic transplantation</strong> –<strong> </strong>The optimal site for heterotopic transplant of ovarian tissue is not known. Ovarian tissue has been placed in subcutaneous tissue of the forearm and lower abdomen [<a href="#rid164">164,165</a>]. The first ongoing pregnancy following heterotopic grafting of cryopreserved ovarian tissue was reported in a patient who had previously undergone bilateral oophorectomy for a granulosa cell tumor [<a href="#rid116">116</a>]. After transplantation of frozen-thawed ovarian tissue to her anterior abdominal wall, she underwent ovarian stimulation with retrieval of two oocytes followed by IVF with intracytoplasmic sperm injection. </p><p></p><p class="bulletIndent1">In women planning to undergo radiation therapy to the pelvis, autotransplantation of a fresh ovary to the upper extremity with creation of vascular anastomosis would remove the ovary from the radiation field and thus protect it from radiation damage [<a href="#rid166">166,167</a>] (see  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery", section on 'Autotransplantation'</a>). Ideally, the ovary would then continue to produce hormones and oocytes, which could be aspirated for IVF. However, studies suggest that the lifespan of autotransplanted ovarian grafts may be limited to less than three years, mainly owing to the loss of a substantial number of follicles during the ischemic period of the revascularization process immediately after transplantation [<a href="#rid163">163,165,168,169</a>].</p><p></p><p class="bulletIndent1">In chemotherapy patients, autologous heterotopic transplantation of a fresh ovary or ovarian tissue would not be useful since the effects of chemotherapy are systemic. However, autologous heterotopic transplantation of cryopreserved ovarian tissue after chemotherapy could be an option in these patients. </p><p></p><p class="bulletIndent1">Large clinical studies are needed to determine the true efficiency of the OTT procedure and to determine the optimal surgical technique [<a href="#rid170">170,171</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonautologous orthotopic transplantation</strong> –<strong> </strong>Nonautologous orthotopic transplantation is not a fertility preservation procedure; rather it has been proposed as infertility treatment for patients with primary ovarian insufficiency or who may have an identical twin [<a href="#rid113">113</a>]. Though live births have been reported following this approach, egg donation may be more practical then nonautologous ovarian transplantation because of two major disadvantages to this approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the ovarian tissue is removed from a donor, the donor may be put at higher risk of premature ovarian failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Since an immunologically identical donor is needed, there are few potential candidates for this procedure.</p><p></p><p class="headingAnchor" id="H2951034971"><span class="h2">Semen or spermatozoa</span><span class="headingEndMark"> — </span>Cryopreservation of semen or spermatozoa is a well-established technique that should be offered to all postpubertal boys and adults undergoing gonadotoxic treatment [<a href="#rid29">29,50</a>]. </p><p>Spermatozoa may be damaged by freezing and thawing [<a href="#rid25">25</a>]. Recovery of motile sperm after thawing is less likely in men with severe oligospermia and possibly those with testicular cancer or a basal semen parameter below the 5<sup>th</sup> percentile of the World Health Organization reference value [<a href="#rid172">172</a>].</p><p class="headingAnchor" id="H1209915475"><span class="h2">Testicular tissue</span><span class="headingEndMark"> — </span>Testicular tissue preservation and tissue grafting/reimplantation are techniques for fertility preservation, particularly in prepubertal boys [<a href="#rid29">29,50</a>]. While these procedures are offered in some countries, they are considered investigational in others.</p><p class="headingAnchor" id="H2592727967"><span class="h1">RESOURCES FOR PATIENTS AND CLINICIANS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.net%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLJozeQq2ELYlI1Q0T9FaQ%2FA%3D&amp;TOPIC_ID=121395" target="_blank">Cancer.Net</a> – A website for patients by the American Society of Clinical Oncology (ASCO)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.reproductivefacts.org%2F%3Fvs%3D1%26_ga%3D2.32389180.325440232.1559224615-111960634.1559224615&amp;token=AZlKznUHE9vIqI5wbXf76ZtcmvE31NFaUh8jHYIQ5jkwt5TmtSt1VMXPJA5j%2B%2BHiby5aqU2ooaxskMpx%2B0ZjiVEdCuhpU8KnVzpwCIs6JuA0SmkfFTWYcsjztMdJgkEn&amp;TOPIC_ID=121395" target="_blank">ReproductiveFacts.org</a> – A website for patients by the American Society for Reproductive Medicine (ASRM)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.livestrong.org%2Fwe-can-help&amp;token=X6pqtZnY0%2FxnhfBU%2FZxbb%2BCyuJTk66Bi2Cs5hm5OYJTYDUHbYxvbINMoi2aa2Zsw&amp;TOPIC_ID=121395" target="_blank">LIVESTRONG Fertility</a> – Provides information on treatment and eligibility for discounted rates for fertility preservation interventions </p><p></p><p class="headingAnchor" id="H1754241890"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114191.html" rel="external">"Society guideline links: Female infertility"</a>.)</p><p class="headingAnchor" id="H1598295374"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83955.html" rel="external">"Patient education: Preserving fertility after cancer treatment in children (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83956.html" rel="external">"Patient education: Preserving fertility after cancer treatment in men (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83957.html" rel="external">"Patient education: Preserving fertility after cancer treatment in women (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2668278075"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates</strong> – Any reproductive-age patient considering gonadotoxic therapy or surgery and who wishes to preserve future fertility is a candidate for cryopreservation techniques. Postpubertal children and adults with cancer or medical diseases  (<a class="graphic graphic_table graphicRef60344" href="/d/graphic/60344.html" rel="external">table 1</a>) that require gonadotoxic therapy  (<a class="graphic graphic_table graphicRef58142" href="/d/graphic/58142.html" rel="external">table 2</a>) have traditionally been referred for a fertility consultation. Additional candidates include patients undergoing gonad extirpation as part of gender affirmation surgery, those undergoing gonadal surgery for benign lesions, or prepubertal children. (See <a class="local">'Candidates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment procedures</strong> – Pretreatment involves procedures to obtain the cells, and potentially create the embryos, that will then be cryopreserved for future use. Typical procedures include ovarian stimulation and oocyte retrieval, semen or sperm collection, and in vitro fertilization (IVF). (See <a class="local">'Pretreatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Established cryopreservation techniques</strong> – Established cryopreservation techniques now include freezing of embryos, oocytes, ovarian tissue, and spermatozoa  (<a class="graphic graphic_table graphicRef65144" href="/d/graphic/65144.html" rel="external">table 3</a>). Cryopreservation of testicular tissue is available in some centers and offered only as part of a research protocol [<a href="#rid53">53</a>]. (See <a class="local">'Cryopreservation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Embryos </strong>– Embryo cryopreservation is the longest-used fertility preservation technique. However, it may not be medically feasible for all patients and not all patients have partners. (See <a class="local">'Embryo'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mature oocytes</strong> – Cryopreservation of mature oocytes is an option for women without partners, women who may have partners but are concerned about the practical limitations with embryo cryopreservation, or women who opt not to use donor sperm for IVF. Retrieval of immature oocytes followed by in vitro maturation has also been performed. Advantages include avoidance of large doses of gonadotropins and fewer time constraints. (See <a class="local">'Oocytes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovarian tissue</strong>– Cryopreservation of ovarian tissue is becoming more widely available. This technique has the advantage of restoring ovarian endocrine function as well as the ability to conceive. Cryopreservation of ovarian tissue is not an ideal option for women with ovarian cancer or those at high risk of developing ovarian cancer. (See <a class="local">'Ovary'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sperm</strong> – We offer cryopreservation of sperm to all postpubertal male cancer patients before starting cytotoxic therapy. (See <a class="local">'Semen or spermatozoa'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-thaw survival</strong> – There is no evidence to support the statement that cryopreserved embryos, oocytes, or ovarian tissue deteriorates with long-term storage, and clinical experience demonstrates that they can be viably stored for decades. Frozen embryos survive the freeze-thaw process somewhat better than unfertilized oocytes (&gt;90 percent survival versus over 70 percent survival). (See <a class="local">'Freeze-thaw survival'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Finch A, Valentini A, Greenblatt E, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 2013; 99:1724.</a></li><li><a class="nounderline abstract_t">Lin WT, Beattie M, Chen LM, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 2013; 119:1652.</a></li><li><a class="nounderline abstract_t">Rzepka-Górska I, Tarnowski B, Chudecka-Głaz A, et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006; 100:59.</a></li><li><a class="nounderline abstract_t">Turan V, Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum Reprod Update 2020; 26:43.</a></li><li><a class="nounderline abstract_t">Turan V, Lambertini M, Lee DY, et al. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. J Clin Oncol 2021; 39:2016.</a></li><li><a class="nounderline abstract_t">Lin W, Titus S, Moy F, et al. Ovarian Aging in Women With BRCA Germline Mutations. J Clin Endocrinol Metab 2017; 102:3839.</a></li><li><a class="nounderline abstract_t">Oktay K, Moy F, Titus S, et al. Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J Clin Oncol 2014; 32:1093.</a></li><li><a class="nounderline abstract_t">Oktay KH, Bedoschi G, Goldfarb SB, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril 2020; 113:1251.</a></li><li><a class="nounderline abstract_t">Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011; 95:2125.e9.</a></li><li><a class="nounderline abstract_t">İsrafilova G, Şükür YE, Özkavukcu S, et al. Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation. Reprod Sci 2021; 28:2200.</a></li><li><a class="nounderline abstract_t">Ubaldi F, Rienzi L, Ferrero S, et al. Natural in vitro fertilization cycles. Ann N Y Acad Sci 2004; 1034:245.</a></li><li><a class="nounderline abstract_t">Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg 2009; 209:603.</a></li><li><a class="nounderline abstract_t">Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril 2001; 75:705.</a></li><li><a class="nounderline abstract_t">Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril 2005; 83:897.</a></li><li><a class="nounderline abstract_t">Barton SE, Missmer SA, Berry KF, Ginsburg ES. Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies. Fertil Steril 2012; 97:381.</a></li><li><a class="nounderline abstract_t">Senapati S, Morse CB, Sammel MD, et al. Fertility preservation in patients with haematological disorders: a retrospective cohort study. Reprod Biomed Online 2014; 28:92.</a></li><li><a class="nounderline abstract_t">Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One 2011; 6:e19475.</a></li><li><a class="nounderline abstract_t">Titus S, Szymanska KJ, Musul B, et al. Individual-oocyte transcriptomic analysis shows that genotoxic chemotherapy depletes human primordial follicle reserve in vivo by triggering proapoptotic pathways without growth activation. Sci Rep 2021; 11:407.</a></li><li><a class="nounderline abstract_t">Lawrenz B, Banys M, Henes M, et al. Pregnancy after breast cancer: case report and review of the literature. Arch Gynecol Obstet 2011; 283:837.</a></li><li><a class="nounderline abstract_t">Rossi BV, Ashby RK, Srouji SS. Embryo banking between induction and consolidation chemotherapy in women with leukemia. Fertil Steril 2011; 96:1412.</a></li><li><a class="nounderline abstract_t">Goldfarb SB, Turan V, Bedoschi G, et al. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Res Treat 2021; 185:165.</a></li><li><a class="nounderline abstract_t">Pittaway DE, Wentz AC. Evaluation of the exponential rise of serum estradiol concentrations in human menopausal gonadotropin-induced cycles. Fertil Steril 1983; 40:763.</a></li><li><a class="nounderline abstract_t">Peña JE, Chang PL, Chan LK, et al. Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. Hum Reprod 2002; 17:83.</a></li><li><a class="nounderline abstract_t">Chen CH, Zhang X, Barnes R, et al. Relationship between peak serum estradiol levels and treatment outcome in in vitro fertilization cycles after embryo transfer on day 3 or day 5. Fertil Steril 2003; 80:75.</a></li><li><a class="nounderline abstract_t">Palomar Rios A, Gascón A, Martínez JV, et al. Sperm preparation after freezing improves motile sperm count, motility, and viability in frozen-thawed sperm compared with sperm preparation before freezing-thawing process. J Assist Reprod Genet 2018; 35:237.</a></li><li><a class="nounderline abstract_t">Dahhan T, Balkenende E, van Wely M, et al. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. Cochrane Database Syst Rev 2013; :CD010240.</a></li><li><a class="nounderline abstract_t">Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod 2017; 32:1033.</a></li><li><a class="nounderline abstract_t">Dahhan T, Balkenende EME, Beerendonk CCM, et al. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. Contemp Clin Trials 2017; 61:96.</a></li><li><a class="nounderline abstract_t">Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36:1994.</a></li><li><a class="nounderline abstract_t">Garrido-Marín M, Argacha PM, Fernández L, et al. Full-term pregnancy in breast cancer survivor with fertility preservation: A case report and review of literature. World J Clin Cases 2019; 7:58.</a></li><li><a class="nounderline abstract_t">Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23:4347.</a></li><li><a class="nounderline abstract_t">Fatemi HM, Kolibianakis E, Tournaye H, et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003; 7:543.</a></li><li><a class="nounderline abstract_t">Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007; 92:2197.</a></li><li><a class="nounderline abstract_t">Bonardi B, Massarotti C, Bruzzone M, et al. Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Front Oncol 2020; 10:574669.</a></li><li><a class="nounderline abstract_t">Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab 2016; 101:1364.</a></li><li><a class="nounderline abstract_t">Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013; 100:1681.</a></li><li><a class="nounderline abstract_t">Boostanfar R, Jain JK, Mishell DR Jr, Paulson RJ. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001; 75:1024.</a></li><li class="breakAll">Oktay K, Sonmezer M, Yale University School of Medicine (US) and Ankara University School of Medicine (Turkey), 2019, personal communication.</li><li><a class="nounderline abstract_t">Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003; 18:90.</a></li><li><a class="nounderline abstract_t">Meirow D, Raanani H, Maman E, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 2014; 102:488.</a></li><li><a class="nounderline abstract_t">Letourneau J, Juarez-Hernandez F, Wald K, et al. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. J Assist Reprod Genet 2021; 38:2455.</a></li><li><a class="nounderline abstract_t">Creux H, Monnier P, Son WY, et al. Immature oocyte retrieval and in vitro oocyte maturation at different phases of the menstrual cycle in women with cancer who require urgent gonadotoxic treatment. Fertil Steril 2017; 107:198.</a></li><li><a class="nounderline abstract_t">Daudin M, Rives N, Walschaerts M, et al. Sperm cryopreservation in adolescents and young adults with cancer: results of the French national sperm banking network (CECOS). Fertil Steril 2015; 103:478.</a></li><li><a class="nounderline abstract_t">Bahadur G, Ling KL, Hart R, et al. Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod 2002; 17:3157.</a></li><li><a class="nounderline abstract_t">Hagenäs I, Jørgensen N, Rechnitzer C, et al. Clinical and biochemical correlates of successful semen collection for cryopreservation from 12-18-year-old patients: a single-center study of 86 adolescents. Hum Reprod 2010; 25:2031.</a></li><li><a class="nounderline abstract_t">Williams DH 4th, Karpman E, Sander JC, et al. Pretreatment semen parameters in men with cancer. J Urol 2009; 181:736.</a></li><li><a class="nounderline abstract_t">Chan PT, Palermo GD, Veeck LL, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001; 92:1632.</a></li><li><a class="nounderline abstract_t">Köhn FM, Schroeder-Printzen I, Weidner W, et al. Testicular sperm extraction in a patient with metachronous bilateral testicular cancer. Hum Reprod 2001; 16:2343.</a></li><li><a class="nounderline abstract_t">Adank MC, van Dorp W, Smit M, et al. Electroejaculation as a method of fertility preservation in boys diagnosed with cancer: a single-center experience and review of the literature. Fertil Steril 2014; 102:199.</a></li><li><a class="nounderline abstract_t">Ethics Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="642537362924051716094a0b1603">[email protected]</span>. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril 2018; 110:380.</a></li><li><a class="nounderline abstract_t">Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Hum Reprod 2017; 32:1802.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="0e6f7d7c634e6f7d7c6320617c69">[email protected]</span>. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2019; 112:1022.</a></li><li><a class="nounderline abstract_t">Babayev SN, Arslan E, Kogan S, et al. Evaluation of ovarian and testicular tissue cryopreservation in children undergoing gonadotoxic therapies. J Assist Reprod Genet 2013; 30:3.</a></li><li><a class="nounderline abstract_t">Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006; 86:70.</a></li><li><a class="nounderline abstract_t">Seshadri S, Saab W, Exeter H, et al. Clinical outcomes of a vitrified donor oocyte programme: A single UK centre experience. Eur J Obstet Gynecol Reprod Biol 2018; 225:136.</a></li><li><a class="nounderline abstract_t">Cil AP, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril 2013; 100:492.</a></li><li><a class="nounderline abstract_t">Goldman KN, Noyes NL, Knopman JM, et al. Oocyte efficiency: does live birth rate differ when analyzing cryopreserved and fresh oocytes on a per-oocyte basis? Fertil Steril 2013; 100:712.</a></li><li><a class="nounderline abstract_t">Kushnir VA, Barad DH, Albertini DF, et al. Outcomes of Fresh and Cryopreserved Oocyte Donation. JAMA 2015; 314:623.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="6a0b1918072a0b1918074405180d">[email protected]</span>. Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline. Fertil Steril 2021; 116:36.</a></li><li class="breakAll">Ozgur K and Oktay K. Utility of PGS to determine the need for repeat emryo cryopreservation cycles and improve fertility preservation success in cancer patients. 64th Annaul Meeting of the Society for Reproductive Investigation. Orlando, FL 2014.</li><li><a class="nounderline abstract_t">Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. World J Clin Oncol 2017; 8:241.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Assisted Reproductive Technology. 2008 Assisted Reproductive Technology Report. http://www.cdc.gov/art/ART2008/section3.htm (Accessed on May 17, 2011).</li><li class="breakAll">SART National Summary Report. Preliminary Clinic Summary Report for 2016. Society of Assisted Reproductive Technology. 2018 www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2016 (Accessed on October 25, 2018).</li><li><a class="nounderline abstract_t">Oktay K, Turan V, Bedoschi G, et al. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol 2015; 33:2424.</a></li><li><a class="nounderline abstract_t">Anderson RA, Kinniburgh D, Baird DT. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod 1999; 14:2665.</a></li><li><a class="nounderline abstract_t">Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet 2010; 27:491.</a></li><li><a class="nounderline abstract_t">von Wolff M, Thaler CJ, Frambach T, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009; 92:1360.</a></li><li><a class="nounderline abstract_t">Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013; 100:1673.</a></li><li><a class="nounderline abstract_t">Gosden RG. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 2005; :60.</a></li><li><a class="nounderline abstract_t">Porcu E, Venturoli S. Progress with oocyte cryopreservation. Curr Opin Obstet Gynecol 2006; 18:273.</a></li><li><a class="nounderline abstract_t">Jain JK, Paulson RJ. Oocyte cryopreservation. Fertil Steril 2006; 86:1037.</a></li><li><a class="nounderline abstract_t">Papatheodorou A, Vanderzwalmen P, Panagiotidis Y, et al. Open versus closed oocyte vitrification system: a prospective randomized sibling-oocyte study. Reprod Biomed Online 2013; 26:595.</a></li><li><a class="nounderline abstract_t">Wang CT, Liang L, Witz C, et al. Optimized protocol for cryopreservation of human eggs improves developmental competence and implantation of resulting embryos. J Ovarian Res 2013; 6:15.</a></li><li><a class="nounderline abstract_t">Cobo A, Kuwayama M, Pérez S, et al. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2008; 89:1657.</a></li><li><a class="nounderline abstract_t">Parmegiani L, Cognigni GE, Bernardi S, et al. Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes. Reprod Biomed Online 2011; 23:505.</a></li><li><a class="nounderline abstract_t">Rienzi L, Romano S, Albricci L, et al. Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reprod 2010; 25:66.</a></li><li><a class="nounderline abstract_t">Cobo A, Meseguer M, Remohí J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod 2010; 25:2239.</a></li><li><a class="nounderline abstract_t">Borini A, Levi Setti PE, Anserini P, et al. Multicenter observational study on slow-cooling oocyte cryopreservation: clinical outcome. Fertil Steril 2010; 94:1662.</a></li><li><a class="nounderline abstract_t">Scaravelli G, Vigiliano V, Mayorga JM, et al. Analysis of oocyte cryopreservation in assisted reproduction: the Italian National Register data from 2005 to 2007. Reprod Biomed Online 2010; 21:496.</a></li><li><a class="nounderline abstract_t">Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2011; 96:277.</a></li><li><a class="nounderline abstract_t">Levi-Setti PE, Patrizio P, Scaravelli G. Evolution of human oocyte cryopreservation: slow freezing versus vitrification. Curr Opin Endocrinol Diabetes Obes 2016; 23:445.</a></li><li class="breakAll">Success Rate Calculator. Innovation Fertility Preservation &amp; IVF. www.fertilitypreservation.org/contents/probability-calculator (Accessed on May 29, 2019).</li><li><a class="nounderline abstract_t">Oktay K, Bedoschi G, Berkowitz K, et al. Fertility Preservation in Women with Turner Syndrome: A Comprehensive Review and Practical Guidelines. J Pediatr Adolesc Gynecol 2016; 29:409.</a></li><li><a class="nounderline abstract_t">Oktay K, Bedoschi G. Oocyte cryopreservation for fertility preservation in postpubertal female children at risk for premature ovarian failure due to accelerated follicle loss in Turner syndrome or cancer treatments. J Pediatr Adolesc Gynecol 2014; 27:342.</a></li><li><a class="nounderline abstract_t">Oktay K, Rodriguez-Wallberg KA, Sahin G. Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure. Fertil Steril 2010; 94:753.e15.</a></li><li><a class="nounderline abstract_t">Sönmezer M, Gülümser Ç, Sönmezer M, et al. Transabdominal ultrasound guided oocyte retrieval using vaginal ultrasound probe: Definition of the technique. J Obstet Gynaecol Res 2021; 47:800.</a></li><li><a class="nounderline abstract_t">Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion. Fertil Steril 2007; 88:1495.</a></li><li><a class="nounderline abstract_t">Huang JY, Tulandi T, Holzer H, et al. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008; 89:567.</a></li><li><a class="nounderline abstract_t">Prasath EB, Chan ML, Wong WH, et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod 2014; 29:276.</a></li><li><a class="nounderline abstract_t">Abir R, Ben-Aharon I, Garor R, et al. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy. Hum Reprod 2016; 31:750.</a></li><li><a class="nounderline abstract_t">Ata B, Shalom-Paz E, Chian RC, Tan SL. In vitro maturation of oocytes as a strategy for fertility preservation. Clin Obstet Gynecol 2010; 53:775.</a></li><li><a class="nounderline abstract_t">Telfer EE, McLaughlin M. In vitro development of ovarian follicles. Semin Reprod Med 2011; 29:15.</a></li><li><a class="nounderline abstract_t">Cao Y, Xing Q, Zhang ZG, et al. Cryopreservation of immature and in-vitro matured human oocytes by vitrification. Reprod Biomed Online 2009; 19:369.</a></li><li><a class="nounderline abstract_t">Wang H, Racowsky C, Combelles CM. Is it best to cryopreserve human cumulus-free immature oocytes before or after in vitro maturation? Cryobiology 2012; 65:79.</a></li><li><a class="nounderline abstract_t">Lee JA, Barritt J, Moschini RM, et al. Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? Fertil Steril 2013; 99:1356.</a></li><li><a class="nounderline abstract_t">Karavani G, Schachter-Safrai N, Revel A, et al. In vitro maturation rates in young premenarche patients. Fertil Steril 2019; 112:315.</a></li><li><a class="nounderline abstract_t">Jurema MW, Nogueira D. In vitro maturation of human oocytes for assisted reproduction. Fertil Steril 2006; 86:1277.</a></li><li><a class="nounderline abstract_t">Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril 2013; 99:663.</a></li><li><a class="nounderline abstract_t">Walls ML, Hart RJ. In vitro maturation. Best Pract Res Clin Obstet Gynaecol 2018; 53:60.</a></li><li><a class="nounderline abstract_t">Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010; 20:634.</a></li><li><a class="nounderline abstract_t">Chian RC, Gilbert L, Huang JY, et al. Live birth after vitrification of in vitro matured human oocytes. Fertil Steril 2009; 91:372.</a></li><li><a class="nounderline abstract_t">Söderström-Anttila V, Salokorpi T, Pihlaja M, et al. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006; 21:1508.</a></li><li><a class="nounderline abstract_t">Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril 2009; 91:2391.</a></li><li><a class="nounderline abstract_t">Imhof M, Hofstetter G, Bergmeister lH, et al. Cryopreservation of a whole ovary as a strategy for restoring ovarian function. J Assist Reprod Genet 2004; 21:459.</a></li><li><a class="nounderline abstract_t">Revel A, Elami A, Bor A, et al. Whole sheep ovary cryopreservation and transplantation. Fertil Steril 2004; 82:1714.</a></li><li><a class="nounderline abstract_t">Imhof M, Bergmeister H, Lipovac M, et al. Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth. Fertil Steril 2006; 85 Suppl 1:1208.</a></li><li><a class="nounderline abstract_t">Bedaiwy MA, Hussein MR, Biscotti C, Falcone T. Cryopreservation of intact human ovary with its vascular pedicle. Hum Reprod 2006; 21:3258.</a></li><li><a class="nounderline abstract_t">Martinez-Madrid B, Camboni A, Dolmans MM, et al. Apoptosis and ultrastructural assessment after cryopreservation of whole human ovaries with their vascular pedicle. Fertil Steril 2007; 87:1153.</a></li><li><a class="nounderline abstract_t">Demeestere I, Simon P, Buxant F, et al. Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report. Hum Reprod 2006; 21:2010.</a></li><li><a class="nounderline abstract_t">Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364:1405.</a></li><li><a class="nounderline abstract_t">Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353:318.</a></li><li><a class="nounderline abstract_t">Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: what is the explanation? Fertil Steril 2011; 95:804.e7.</a></li><li><a class="nounderline abstract_t">Silber SJ, DeRosa M, Pineda J, et al. A series of monozygotic twins discordant for ovarian failure: ovary transplantation (cortical versus microvascular) and cryopreservation. Hum Reprod 2008; 23:1531.</a></li><li><a class="nounderline abstract_t">Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008; 23:2266.</a></li><li><a class="nounderline abstract_t">Oktay K, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004; 364:2091.</a></li><li><a class="nounderline abstract_t">Stern CJ, Gook D, Hale LG, et al. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod 2013; 28:2996.</a></li><li><a class="nounderline abstract_t">Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril 2014; 101:1237.</a></li><li><a class="nounderline abstract_t">Pacheco F, Oktay K. Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. Reprod Sci 2017; 24:1111.</a></li><li><a class="nounderline abstract_t">Sugishita Y, Okamoto N, Uekawa A, et al. Oocyte retrieval after heterotopic transplantation of ovarian tissue cryopreserved by closed vitrification protocol. J Assist Reprod Genet 2018; 35:2037.</a></li><li><a class="nounderline abstract_t">Corral A, Clavero M, Gallardo M, et al. Ovarian tissue cryopreservation by stepped vitrification and monitored by X-ray computed tomography. Cryobiology 2018; 81:17.</a></li><li><a class="nounderline abstract_t">Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007; 110:2222.</a></li><li><a class="nounderline abstract_t">Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007; 67:10159.</a></li><li><a class="nounderline abstract_t">Oktay K, Bedoschi G, Pacheco F, et al. First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery. Am J Obstet Gynecol 2016; 214:94.e1.</a></li><li><a class="nounderline abstract_t">Huober-Zeeb C, Lawrenz B, Popovici RM, et al. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril 2011; 95:342.</a></li><li><a class="nounderline abstract_t">Fasano G, Dechène J, Antonacci R, et al. Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients. Reprod Biomed Online 2017; 34:575.</a></li><li><a class="nounderline abstract_t">Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005; 6:209.</a></li><li><a class="nounderline abstract_t">Anderson RA, Wallace WH, Baird DT. Ovarian cryopreservation for fertility preservation: indications and outcomes. Reproduction 2008; 136:681.</a></li><li><a class="nounderline abstract_t">Oktay K. Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age. J Clin Endocrinol Metab 2002; 87:1907.</a></li><li><a class="nounderline abstract_t">Telfer EE, McLaughlin M. Strategies to support human oocyte development in vitro. Int J Dev Biol 2012; 56:901.</a></li><li><a class="nounderline abstract_t">Dolmans MM, Jadoul P, Gilliaux S, et al. A review of 15 years of ovarian tissue bank activities. J Assist Reprod Genet 2013; 30:305.</a></li><li><a class="nounderline abstract_t">Oktay K, Marin L, Bedoschi G, et al. Ovarian transplantation with robotic surgery and a neovascularizing human extracellular matrix scaffold: a case series in comparison to meta-analytic data. Fertil Steril 2022; 117:181.</a></li><li><a class="nounderline abstract_t">Oktay KH, Marin L, Titus S. Impact of chemotherapy on the ovarian reserve: Are all primordial follicles created equal? Fertil Steril 2022; 117:396.</a></li><li><a class="nounderline abstract_t">Bedoschi GM, Navarro PA, Oktay KH. Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary. Panminerva Med 2019; 61:68.</a></li><li><a class="nounderline abstract_t">Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY) 2011; 3:782.</a></li><li class="breakAll">Oktay K, Bedoschi G. Surgical Approach to Laparoscopic and Robot-Assisted Ovarian Tissue Transplantation. In: Principles and Practice of Ovarian Tissue Cryopreservation and Transplantation, Oktay K (Ed), Elsevier, 2022. p.159.</li><li class="breakAll">Society for Assisted Reproductive Technology. IVF success rates. Clinic summary report 2009. https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0 (Accessed on May 17, 2011).</li><li><a class="nounderline abstract_t">Lotz L, Bender-Liebenthron J, Dittrich R, et al. Determinants of transplantation success with cryopreserved ovarian tissue: data from 196 women of the FertiPROTEKT network. Hum Reprod 2022; 37:2787.</a></li><li><a class="nounderline abstract_t">Donnez J, Dolmans MM, Pellicer A, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril 2013; 99:1503.</a></li><li><a class="nounderline abstract_t">Imbert R, Moffa F, Tsepelidis S, et al. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod 2014; 29:1931.</a></li><li><a class="nounderline abstract_t">Demeestere I, Simon P, Dedeken L, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod 2015; 30:2107.</a></li><li class="breakAll">BBC News Health. Woman has baby using ovary frozen in childhood. BBC News. December 2016. http://www.bbc.com/news/health-38312995 (Accessed on December 16, 2016).</li><li><a class="nounderline abstract_t">Dolmans MM, von Wolff M, Poirot C, et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil Steril 2021; 115:1102.</a></li><li><a class="nounderline abstract_t">Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609.</a></li><li><a class="nounderline abstract_t">Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol 1994; 84:449.</a></li><li><a class="nounderline abstract_t">Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10:251.</a></li><li><a class="nounderline abstract_t">Greve T, Wielenga VT, Grauslund M, et al. Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination. Eur J Cancer 2013; 49:1932.</a></li><li><a class="nounderline abstract_t">Elassar A, Oktem O, Oktay K. Fertility preservation with ovarian cryopreservation: a decade of experience. Fertil Steril 2007; 88:S12.</a></li><li><a class="nounderline abstract_t">Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010; 116:2908.</a></li><li><a class="nounderline abstract_t">Meirow D, Hardan I, Dor J, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod 2008; 23:1007.</a></li><li><a class="nounderline abstract_t">Rosendahl M, Andersen MT, Ralfkiær E, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010; 94:2186.</a></li><li><a class="nounderline abstract_t">Bastings L, Beerendonk CC, Westphal JR, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update 2013; 19:483.</a></li><li><a class="nounderline abstract_t">Shapira M, Raanani H, Barshack I, et al. First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. Fertil Steril 2018; 109:48.</a></li><li><a class="nounderline abstract_t">Sonmezer M, Ozkavukcu S, Sukur YE, et al. First pregnancy and live birth in Turkey following frozen-thawed ovarian tissue transplantation in a patient with acute lymphoblastic leukemia who underwent cord blood transplantation. J Assist Reprod Genet 2020; 37:2033.</a></li><li><a class="nounderline abstract_t">Sonmezer M, Sükür YE, Saçinti KG, et al. Is it safe to perform ovarian cryopreservation and transplantation in patients with leukemia: a 5-year survival analysis data. Fertil Steril 2022; 118:e202.</a></li><li><a class="nounderline abstract_t">Shaw JM, Bowles J, Koopman P, et al. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients. Hum Reprod 1996; 11:1668.</a></li><li><a class="nounderline abstract_t">Kim SS, Radford J, Harris M, et al. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod 2001; 16:2056.</a></li><li><a class="nounderline abstract_t">Seshadri T, Gook D, Lade S, et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer 2006; 94:1007.</a></li><li><a class="nounderline abstract_t">Oktay KH, Yih M. Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips. Semin Reprod Med 2002; 20:63.</a></li><li><a class="nounderline abstract_t">Donnez J, Dolmans MM. Cryopreservation and transplantation of ovarian tissue. Clin Obstet Gynecol 2010; 53:787.</a></li><li><a class="nounderline abstract_t">Bedaiwy MA, Falcone T. Whole ovary transplantation. Clin Obstet Gynecol 2010; 53:797.</a></li><li><a class="nounderline abstract_t">Taylan E, Oktay K. Application of Decellularized Tissue Scaffolds in Ovarian Tissue Transplantation. Methods Mol Biol 2018; 1577:177.</a></li><li><a class="nounderline abstract_t">Jensen AK, Kristensen SG, Macklon KT, et al. Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod 2015; 30:2838.</a></li><li><a class="nounderline abstract_t">Kim SS, Lee WS, Chung MK, et al. Long-term ovarian function and fertility after heterotopic autotransplantation of cryobanked human ovarian tissue: 8-year experience in cancer patients. Fertil Steril 2009; 91:2349.</a></li><li><a class="nounderline abstract_t">Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 363:837.</a></li><li><a class="nounderline abstract_t">Oktay K, Economos K, Kan M, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001; 286:1490.</a></li><li><a class="nounderline abstract_t">Leporrier M, von Theobald P, Roffe JL, Muller G. A new technique to protect ovarian function before pelvic irradiation. Heterotopic ovarian autotransplantation. Cancer 1987; 60:2201.</a></li><li><a class="nounderline abstract_t">Hilders CG, Baranski AG, Peters L, et al. Successful human ovarian autotransplantation to the upper arm. Cancer 2004; 101:2771.</a></li><li><a class="nounderline abstract_t">Radford JA, Lieberman BA, Brison DR, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 2001; 357:1172.</a></li><li><a class="nounderline abstract_t">Wølner-Hanssen P, Hägglund L, Ploman F, et al. Autotransplantation of cryopreserved ovarian tissue to the right forearm 4(1/2) years after autologous stem cell transplantation. Acta Obstet Gynecol Scand 2005; 84:695.</a></li><li><a class="nounderline abstract_t">Oktay K. Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? Hum Reprod 2006; 21:1345.</a></li><li><a class="nounderline abstract_t">Bedaiwy MA, Shahin AY, Falcone T. Reproductive organ transplantation: advances and controversies. Fertil Steril 2008; 90:2031.</a></li><li><a class="nounderline abstract_t">Degl'Innocenti S, Filimberti E, Magini A, et al. Semen cryopreservation for men banking for oligospermia, cancers, and other pathologies: prediction of post-thaw outcome using basal semen quality. Fertil Steril 2013; 100:1555.</a></li></ol></div><div id="topicVersionRevision">Topic 121395 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414920" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362014" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773440" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Premature menopause in patients with BRCA1 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31822904" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33891474" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28938488" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ovarian Aging in Women With BRCA Germline Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24550421" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32331767" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292255" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33409878" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15731316" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Natural in vitro fertilization cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854400" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287023" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : In vitro fertilization for cancer patients and survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of in vitro fertilization after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177464" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140311" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fertility preservation in patients with haematological disorders: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21559342" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33431979" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Individual-oocyte transcriptomic analysis shows that genotoxic chemotherapy depletes human primordial follicle reserve in vivo by triggering proapoptotic pathways without growth activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21221981" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pregnancy after breast cancer: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22130103" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Embryo banking between induction and consolidation chemotherapy in women with leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32930927" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6418575" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of the exponential rise of serum estradiol concentrations in human menopausal gonadotropin-induced cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756366" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849804" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relationship between peak serum estradiol levels and treatment outcome in in vitro fertilization cycles after embryo transfer on day 3 or day 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28990130" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sperm preparation after freezing improves motile sperm count, motility, and viability in frozen-thawed sperm compared with sperm preparation before freezing-thawing process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24213953" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28333356" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28710053" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620997" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30637253" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Full-term pregnancy in breast cancer survivor with fertility preservation: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824416" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14680546" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356042" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33117711" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26751194" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055050" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11334921" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11334921" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525446" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24934489" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34312774" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27810160" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immature oocyte retrieval and in vitro oocyte maturation at different phases of the menstrual cycle in women with cancer who require urgent gonadotoxic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527232" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sperm cryopreservation in adolescents and young adults with cancer: results of the French national sperm banking network (CECOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456617" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Semen quality and cryopreservation in adolescent cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570975" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical and biochemical correlates of successful semen collection for cryopreservation from 12-18-year-old patients: a single-center study of 86 adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091343" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pretreatment semen parameters in men with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745242" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679517" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Testicular sperm extraction in a patient with metachronous bilateral testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780076" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Electroejaculation as a method of fertility preservation in boys diagnosed with cancer: a single-center experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30098684" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29117320" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843073" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23242649" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evaluation of ovarian and testicular tissue cryopreservation in children undergoing gonadotoxic therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818031" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficiency of oocyte cryopreservation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29709727" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical outcomes of a vitrified donor oocyte programme: A single UK centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23706339" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23721713" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Oocyte efficiency: does live birth rate differ when analyzing cryopreserved and fresh oocytes on a per-oocyte basis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26262802" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcomes of Fresh and Cryopreserved Oocyte Donation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34148587" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34148587" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638793" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Current state and controversies in fertility preservation in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638793" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Current state and controversies in fertility preservation in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638793" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Current state and controversies in fertility preservation in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26101247" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10528005" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20455017" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18930226" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23987516" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effective method for emergency fertility preservation: random-start controlled ovarian stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784826" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prospects for oocyte banking and in vitro maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735826" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Progress with oocyte cryopreservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008147" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Oocyte cryopreservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602678" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Open versus closed oocyte vitrification system: a prospective randomized sibling-oocyte study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406718" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Optimized protocol for cryopreservation of human eggs improves developmental competence and implantation of resulting embryos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889865" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21843968" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861328" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20591872" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047739" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Multicenter observational study on slow-cooling oocyte cryopreservation: clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20797902" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Analysis of oocyte cryopreservation in assisted reproduction: the Italian National Register data from 2005 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21718983" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27653002" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evolution of human oocyte cryopreservation: slow freezing versus vitrification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27653002" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Evolution of human oocyte cryopreservation: slow freezing versus vitrification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26485320" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fertility Preservation in Women with Turner Syndrome: A Comprehensive Review and Practical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25214440" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Oocyte cryopreservation for fertility preservation in postpubertal female children at risk for premature ovarian failure due to accelerated follicle loss in Turner syndrome or cancer treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20188362" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33336548" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Transabdominal ultrasound guided oocyte retrieval using vaginal ultrasound probe: Definition of the technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945220" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17543957" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24327539" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848188" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048444" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : In vitro maturation of oocytes as a strategy for fertility preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21207331" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : In vitro development of ovarian follicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19778481" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cryopreservation of immature and in-vitro matured human oocytes by vitrification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691237" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Is it best to cryopreserve human cumulus-free immature oocytes before or after in vitro maturation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266213" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31056316" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : In vitro maturation rates in young premenarche patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996508" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : In vitro maturation of human oocytes for assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23391409" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : In vitro maturation: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30056110" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : In vitro maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219430" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514195" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Live birth after vitrification of in vitro matured human oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449308" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579139" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15704522" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cryopreservation of a whole ovary as a strategy for restoring ovarian function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589891" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Whole sheep ovary cryopreservation and transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616094" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000651" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Cryopreservation of intact human ovary with its vascular pedicle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239875" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Apoptosis and ultrastructural assessment after cryopreservation of whole human ovaries with their vascular pedicle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585122" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15488215" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983020" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20801441" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: what is the explanation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285322" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A series of monozygotic twins discordant for ovarian failure: ovary transplantation (cortical versus microvascular) and cryopreservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18603535" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589298" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Livebirth after cryopreserved ovarian tissue autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24014608" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24684955" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Ovarian tissue cryopreservation: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28701069" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30173352" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Oocyte retrieval after heterotopic transplantation of ovarian tissue cryopreserved by closed vitrification protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518373" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Ovarian tissue cryopreservation by stepped vitrification and monitored by X-ray computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932880" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974956" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26601616" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20797706" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28365199" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811616" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Fertility preservation for young patients with cancer: who is at risk and what can be offered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682546" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Ovarian cryopreservation for fertility preservation: indications and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932340" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23417412" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Strategies to support human oocyte development in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23417329" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A review of 15 years of ovarian tissue bank activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34801235" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Ovarian transplantation with robotic surgery and a neovascularizing human extracellular matrix scaffold: a case series in comparison to meta-analytic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34998576" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Impact of chemotherapy on the ovarian reserve: Are all primordial follicles created equal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29962184" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21869459" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21869459" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21869459" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36272106" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Determinants of transplantation success with cryopreserved ovarian tissue: data from 196 women of the FertiPROTEKT network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635349" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958067" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26062556" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Live birth after autograft of ovarian tissue cryopreserved during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26062556" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Live birth after autograft of ovarian tissue cryopreserved during childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33933173" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023992" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058246" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Ovarian disease in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140872" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Fertility preservation in female patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23452988" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Fertility preservation with ovarian cryopreservation: a decade of experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595517" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344563" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100619" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817363" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198847" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556882" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : First pregnancy and live birth in Turkey following frozen-thawed ovarian tissue transplantation in a patient with acute lymphoblastic leukemia who underwent cord blood transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Is it safe to perform ovarian cryopreservation and transplantation in patients with leukemia: a 5-year survival analysis data</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8921114" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574491" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570049" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941536" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048445" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Cryopreservation and transplantation of ovarian tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048446" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Whole ovary transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510115" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Application of Decellularized Tissue Scaffolds in Ovarian Tissue Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443605" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18675964" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Long-term ovarian function and fertility after heterotopic autotransplantation of cryobanked human ovarian tissue: 8-year experience in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15031026" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Embryo development after heterotopic transplantation of cryopreserved ovarian tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572742" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3440230" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : A new technique to protect ovarian function before pelvic irradiation. Heterotopic ovarian autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534884" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Successful human ovarian autotransplantation to the upper arm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323045" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954881" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Autotransplantation of cryopreserved ovarian tissue to the right forearm 4(1/2) years after autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16459347" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18930221" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Reproductive organ transplantation: advances and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034937" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Semen cryopreservation for men banking for oligospermia, cancers, and other pathologies: prediction of post-thaw outcome using basal semen quality.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
